These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19344396)

  • 21. Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia.
    Bishop S; Matheus MG; Abboud MR; Cane ID; Adams RJ; Jackson SM; Kalpatthi R
    Blood Cells Mol Dis; 2011 Aug; 47(2):125-8. PubMed ID: 21724428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of manual chronic partial exchange transfusion in children with sickle disease.
    Aloni MN; Lê PQ; Heijmans C; Huybrechts S; Devalck C; Azzi N; Ngalula-Mujinga M; Ferster A
    Hematology; 2015 Jun; 20(5):284-8. PubMed ID: 25133935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
    Wood JC; Cohen AR; Pressel SL; Aygun B; Imran H; Luchtman-Jones L; Thompson AA; Fuh B; Schultz WH; Davis BR; Ware RE;
    Br J Haematol; 2016 Jan; 172(1):122-30. PubMed ID: 26523836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis.
    Núñez RM; Figueroa CAP; García-Perdomo HA
    J Child Health Care; 2020 Mar; 24(1):64-77. PubMed ID: 30606035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood transfusion for preventing stroke in people with sickle cell disease.
    Riddington C; Wang W
    Cochrane Database Syst Rev; 2002; (1):CD003146. PubMed ID: 11869654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities.
    Aygun B; Wruck LM; Schultz WH; Mueller BU; Brown C; Luchtman-Jones L; Jackson S; Iyer R; Rogers ZR; Sarnaik S; Thompson AA; Gauger C; Helms RW; Ware RE;
    Am J Hematol; 2012 Apr; 87(4):428-30. PubMed ID: 22231377
    [No Abstract]   [Full Text] [Related]  

  • 29. Patients with sickle cell anemia on simple chronic transfusion protocol show sex differences for hemodynamic and hematologic responses to transfusion.
    Detterich JA; Sangkatumvong S; Kato R; Dongelyan A; Bush A; Khoo M; Meiselman HJ; Coates TD; Wood JC
    Transfusion; 2013 May; 53(5):1059-68. PubMed ID: 23176402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathologic quiz case: a 16-year-old adolescent girl with a trace level of hemoglobin s detected by high-performance liquid chromatography. Almost complete suppression of hemoglobin S in a sickle cell disease patient undergoing long-term transfusion therapy.
    Scurlock D; Risin SA
    Arch Pathol Lab Med; 2005 Apr; 129(4):e107-8. PubMed ID: 15794693
    [No Abstract]   [Full Text] [Related]  

  • 31. [Transfusion in sickle cell anemia].
    Bachir D; Bonnet-Gajdos M; Galacteros F
    Presse Med; 1990 Oct; 19(35):1627-31. PubMed ID: 2147256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.
    Griessenauer CJ; Lebensburger JD; Chua MH; Fisher WS; Hilliard L; Bemrich-Stolz CJ; Howard TH; Johnston JM
    J Neurosurg Pediatr; 2015 Jul; 16(1):64-73. PubMed ID: 25837886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404).
    Chevret S; Verlhac S; Ducros-Miralles E; Dalle JH; de Latour RP; de Montalembert M; Benkerrou M; Pondarré C; Thuret I; Guitton C; Lesprit E; Etienne-Julan M; Elana G; Vannier JP; Lutz P; Neven B; Galambrun C; Paillard C; Runel C; Jubert C; Arnaud C; Kamdem A; Brousse V; Missud F; Petras M; Doumdo-Divialle L; Berger C; Fréard F; Taieb O; Drain E; Elmaleh M; Vasile M; Khelif Y; Bernaudin M; Chadebech P; Pirenne F; Socié G; Bernaudin F
    Contemp Clin Trials; 2017 Nov; 62():91-104. PubMed ID: 28821470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease.
    Wang WC; Kovnar EH; Tonkin IL; Mulhern RK; Langston JW; Day SW; Schell MJ; Wilimas JA
    J Pediatr; 1991 Mar; 118(3):377-82. PubMed ID: 1999776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of automated erythrocytapheresis versus manual exchange transfusion to treat cerebral macrovasculopathy in sickle cell anemia.
    Koehl B; Sommet J; Holvoet L; Abdoul H; Boizeau P; Ithier G; Missud F; Couque N; Verlhac S; Voultoury P; Sellami F; Baruchel A; Benkerrou M
    Transfusion; 2016 May; 56(5):1121-8. PubMed ID: 27021622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential cerebral hemometabolic responses to blood transfusions in adults and children with sickle cell anemia.
    Juttukonda MR; Lee CA; Patel NJ; Davis LT; Waddle SL; Gindville MC; Pruthi S; Kassim AA; DeBaun MR; Donahue MJ; Jordan LC
    J Magn Reson Imaging; 2019 Feb; 49(2):466-477. PubMed ID: 30324698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal Manual Exchange Transfusion Protocol for Sickle Cell Disease: A Retrospective Comparison of Two Comprehensive Care Centers in the United Kingdom and Canada.
    Mian HS; Ward R; Telfer P; Kaya B; Kuo KH
    Hemoglobin; 2015; 39(5):310-5. PubMed ID: 26114740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke.
    Rana S; Houston PE; Surana N; Shalaby-Rana EI; Castro OL
    J Pediatr; 1997 Nov; 131(5):757-60. PubMed ID: 9403661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
    Lagunju I; Brown BJ; Sodeinde O
    Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.